Atlas Venture Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Atlas Venture Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-307,696	Closed	-$12.8M	–	8
2021 Q3	$12.8M	Hold	307,696	–	–	1.52%	5
2021 Q2	$9.34M	Sell	307,696 -305,000	-50%	-$9.22M	0.97%	6
2021 Q1	$18.3M	Hold	612,696	–	–	3.38%	4
2020 Q4	$11M	Sell	612,696 -694,269	-53%	-$13.4M	2.47%	5
2020 Q3	$24.9M	Sell	1,306,965 -55,731	-4%	-$984K	4.19%	3
2020 Q2	$21.4M	Hold	1,362,696	–	–	5.47%	3
2020 Q1	$18.6M	Hold	1,362,696	–	–	25.18%	2
2019 Q4	$12.8M	Hold	1,362,696	–	–	19.41%	2
2019 Q3	$15.5M	Hold	1,362,696	–	–	4.82%	3
2019 Q2	$13.7M	Buy	+1,362,696	New	+$16.4M	5.67%	3

Other funds holding BCYC

RCI

Ridgeback Capital Investments Miami Beach, Florida $560K AUM

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Atlas Venture Advisors's BCYC Position: Q4 2021 in Review

Atlas Venture Advisors sold out of Bicycle Therapeutics (BCYC) in Q4 2021, closing a stake of 307,696 shares — an estimated $12.8M sold.

Atlas Venture Advisors first reported a position in BCYC in Q2 2019 and held it in 10 quarters. The position peaked at $24.9M in Q3 2020. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2021.

Atlas Venture Advisors reported no remaining Bicycle Therapeutics position as of Q4 2021 after selling out during the quarter.
Atlas Venture Advisors sold 307,696 Bicycle Therapeutics shares in Q4 2021, an estimated $12.8M.
Atlas Venture Advisors first reported a position in Bicycle Therapeutics in Q2 2019 and held it in 10 quarters.
Atlas Venture Advisors's Bicycle Therapeutics position peaked at $24.9M in Q3 2020.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2021.

Based on Atlas Venture Advisors's 13F filing for Q4 2021, filed 27 Jan 2022.